The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design

被引:12
|
作者
Bernardo, Miguel [1 ,2 ,3 ,4 ]
Amoretti, Silvia [1 ,2 ,3 ,4 ]
Jesus Cuesta, Manuel [5 ]
Parellada, Mara [3 ,6 ]
Mezquida, Gisela [1 ,2 ,3 ,4 ]
机构
[1] Hosp Clin Barcelona, Barcelona Clin, Neurosci Inst, Schizophrenia Unit, Barcelona, Spain
[2] Univ Barcelona, Dept Med, Inst Neurociencies, Barcelona, Spain
[3] Biomed Res Networking Ctr Mental Hlth Network CIB, Barcelona, Spain
[4] August Pi & Sunyer Biomed Res Inst IDIBAPS, Barcelona, Spain
[5] Complejo Hosp Navarra, Dept Psiquiatria, Inst Invest Sanitaria Navarra IdiSNA, Pamplona, Navarra, Spain
[6] Univ Complutense, Serv Psiquiatria Nino & Adolescente, Hosp Gen Univ Gregorio Maranon IiSGM, Fac Med,CIBERSAM, Madrid, Spain
来源
REVISTA DE PSIQUIATRIA Y SALUD MENTAL | 2021年 / 14卷 / 03期
关键词
First-episode of schizophrenia; Relapse; Schizophrenia; PEPs Project; 2EPs Project; 2-YEAR FOLLOW-UP; CONSENSUS COGNITIVE BATTERY; GLOBAL ASSESSMENT SCALE; 1ST-EPISODE PSYCHOSIS; RATING-SCALE; NONAFFECTIVE PSYCHOSIS; DIAGNOSTIC STABILITY; PREMORBID ADJUSTMENT; FUNCTIONAL OUTCOMES; DISORDERS;
D O I
10.1016/j.rpsm.2020.07.004
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Up to 80% of first-episode psychosis patients suffer a relapse within five years of the remission. Relapse should be an important focus of prevention given the potential harm to the patient and family. It threatens to disrupt their psychosocial recovery, increases the risk of resistance to treatment and has been associated with greater direct and indirect costs for society. Based on a previous project entitled "Genotype-phenotype and environment. Application to a predictive model in first psychotic episodes" (PEPs Project), the project "Clinical and neurobiological determinants of second episodes of schizophrenia. Longitudinal study of first episode of psychosis" was designed, also known as the 2EPs Project. It aimed to identify and characterize those factors that predict a relapse within the years immediately following a first episode. This project has focused on following the clinical course, with neuropsychological assessments, biological and neuroanatomical measures, genetic adherence and physical health monitoring in order to compare a subgroup of patients with a second episode to another group of patients which remains in remission. The main objective of the present article is to describe the rationale of the 2EPs Project, explaining the measurement approach adopted and providing an overview of the selected clinical and functional measures. 2EPs Project is a multicenter, coordinated, naturalistic, longitudinal follow-up study over three years in a Spanish sample of patients in remission after a first-psychotic episode of schizophrenia. It is closely monitoring the clinical course of the cases recruited to compare the subgroup of patients with a second episode to that which remains in remission. The sample is composed of 223 subjects recruited from 15 clinical centres in Spain with experience of the preceding PEPs Study project, albeit 2EPs being an expanded version with new basic groups in biological research. From the total sample recruited, 63 patients presented a relapse (44%). 2EPs arose to characterize first episodes in an exhaustive, novel and multimodal way, thus contributing towards the development of a predictive model of relapse. Identifying the characteristics of patients who relapse could improve early detection and intervention. (C) 2020 SEP y SEPB. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:164 / 176
页数:13
相关论文
共 37 条
  • [21] Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial
    Hennerici, Michael G.
    Bots, Michiel L.
    Ford, Ian
    Laurent, Stephane
    Touboul, Pierre Jean
    CARDIOVASCULAR DRUGS AND THERAPY, 2010, 24 (02) : 175 - 180
  • [22] Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial
    Michael G. Hennerici
    Michiel L. Bots
    Ian Ford
    Stéphane Laurent
    Pierre Jean Touboul
    Cardiovascular Drugs and Therapy, 2010, 24 : 175 - 180
  • [23] Rationale and design of the PREDICE project: cost-effectiveness of type 2 diabetes prevention among high-risk Spanish individuals following lifestyle intervention in real-life primary care setting
    Bernardo Costa
    Joan J Cabré
    Ramon Sagarra
    Oriol Solà-Morales
    Francisco Barrio
    Josep L Piñol
    Xavier Cos
    Bonaventura Bolíbar
    Conxa Castell
    Katarzyna Kissimova-Skarbek
    Jaakko Tuomilehto
    BMC Public Health, 11
  • [24] Rationale and design of the PREDICE project: cost-effectiveness of type 2 diabetes prevention among high-risk Spanish individuals following lifestyle intervention in real-life primary care setting
    Costa, Bernardo
    Cabre, Joan J.
    Sagarra, Ramon
    Sola-Morales, Oriol
    Barrio, Francisco
    Pinol, Josep L.
    Cos, Xavier
    Bolibar, Bonaventura
    Castell, Conxa
    Kissimova-Skarbek, Katarzyna
    Tuomilehto, Jaakko
    BMC PUBLIC HEALTH, 2011, 11
  • [25] The PACIFIC (Prevention of AtherothrombotiC Incidents Following Ischemic Coronary attack) Registry: Rationale and Design of a 2-Year Study in Patients Initially Hospitalised with Acute Coronary Syndrome in Japan
    Katsumi Miyauchi
    Yoshihiro Morino
    Kengo Tsukahara
    Hideki Origasa
    Hiroyuki Daida
    Cardiovascular Drugs and Therapy, 2010, 24 : 77 - 83
  • [26] The PACIFIC (Prevention of AtherothrombotiC Incidents Following Ischemic Coronary attack) Registry: Rationale and Design of a 2-Year Study in Patients Initially Hospitalised with Acute Coronary Syndrome in Japan
    Miyauchi, Katsumi
    Morino, Yoshihiro
    Tsukahara, Kengo
    Origasa, Hideki
    Daida, Hiroyuki
    CARDIOVASCULAR DRUGS AND THERAPY, 2010, 24 (01) : 77 - 83
  • [27] The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design
    Rejdak, Konrad
    Fiedor, Piotr
    Bonek, Robert
    Goch, Aleksander
    Gala-Bladzinska, Agnieszka
    Chelstowski, Waldemar
    Lukasiak, Jacek
    Kiciak, Slawomir
    Dabrowski, Piotr
    Dec, Mateusz
    Krol, Zbigniew J.
    Papuc, Ewa
    Zasybska, Adriana
    Segiet, Agnieszka
    Grieb, Pawe
    CONTEMPORARY CLINICAL TRIALS, 2022, 116
  • [28] Leveraging artificial intelligence and data science techniques in harmonizing, sharing, accessing and analyzing SARS-COV-2/COVID-19 data in Rwanda (LAISDAR Project): study design and rationale
    Aurore Nishimwe
    Charles Ruranga
    Clarisse Musanabaganwa
    Regine Mugeni
    Muhammed Semakula
    Joseph Nzabanita
    Ignace Kabano
    Annie Uwimana
    Jean N. Utumatwishima
    Jean Damascene Kabakambira
    Annette Uwineza
    Lars Halvorsen
    Freija Descamps
    Jared Houghtaling
    Benjamin Burke
    Odile Bahati
    Clement Bizimana
    Stefan Jansen
    Celestin Twizere
    Kizito Nkurikiyeyezu
    Francine Birungi
    Sabin Nsanzimana
    Marc Twagirumukiza
    BMC Medical Informatics and Decision Making, 22
  • [29] Leveraging artificial intelligence and data science techniques in harmonizing, sharing, accessing and analyzing SARS-COV-2/COVID-19 data in Rwanda (LAISDAR Project): study design and rationale
    Nishimwe, Aurore
    Ruranga, Charles
    Musanabaganwa, Clarisse
    Mugeni, Regine
    Semakula, Muhammed
    Nzabanita, Joseph
    Kabano, Ignace
    Uwimana, Annie
    Utumatwishima, Jean N.
    Kabakambira, Jean Damascene
    Uwineza, Annette
    Halvorsen, Lars
    Descamps, Freija
    Houghtaling, Jared
    Burke, Benjamin
    Bahati, Odile
    Bizimana, Clement
    Jansen, Stefan
    Twizere, Celestin
    Nkurikiyeyezu, Kizito
    Birungi, Francine
    Nsanzimana, Sabin
    Twagirumukiza, Marc
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2022, 22 (01)
  • [30] Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial
    Lindhardt, Morten
    Persson, Frederik
    Currie, Gemma
    Pontillo, Claudia
    Beige, Joachim
    Delles, Christian
    von der Leyen, Heiko
    Mischak, Harald
    Navis, Gerjan
    Noutsou, Marina
    Ortiz, Alberto
    Ruggenenti, Piero Luigi
    Rychlik, Ivan
    Spasovski, Goce
    Rossing, Peter
    BMJ OPEN, 2016, 6 (03):